Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 13 | 2025 | 148 | 4.980 |
Why?
|
| Cardiovascular Diseases | 12 | 2026 | 861 | 3.740 |
Why?
|
| Diabetic Nephropathies | 7 | 2026 | 37 | 3.400 |
Why?
|
| Albuminuria | 4 | 2025 | 29 | 2.630 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2026 | 728 | 2.290 |
Why?
|
| Mortality | 3 | 2024 | 160 | 2.220 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 3 | 2024 | 6 | 1.960 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 4 | 2026 | 14 | 1.860 |
Why?
|
| Kidney Failure, Chronic | 4 | 2025 | 196 | 1.840 |
Why?
|
| Naphthyridines | 2 | 2026 | 7 | 1.640 |
Why?
|
| Hyponatremia | 3 | 2022 | 11 | 1.580 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 207 | 1.560 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 220 | 1.550 |
Why?
|
| Metabolic Syndrome | 2 | 2025 | 146 | 1.540 |
Why?
|
| Kidney | 7 | 2025 | 451 | 1.500 |
Why?
|
| Nutrition Surveys | 4 | 2024 | 146 | 1.380 |
Why?
|
| Kidney Diseases | 4 | 2025 | 177 | 1.320 |
Why?
|
| Glomerular Filtration Rate | 6 | 2024 | 120 | 1.320 |
Why?
|
| Biomarkers | 7 | 2026 | 1467 | 1.270 |
Why?
|
| Betacoronavirus | 3 | 2020 | 182 | 1.250 |
Why?
|
| Acute Kidney Injury | 4 | 2024 | 142 | 1.130 |
Why?
|
| Pandemics | 4 | 2020 | 669 | 1.060 |
Why?
|
| Humans | 55 | 2026 | 64770 | 1.030 |
Why?
|
| Amyloidosis | 2 | 2024 | 66 | 1.000 |
Why?
|
| Metabolic Diseases | 1 | 2025 | 59 | 0.850 |
Why?
|
| Adiposity | 1 | 2024 | 83 | 0.840 |
Why?
|
| Creatinine | 5 | 2024 | 135 | 0.790 |
Why?
|
| Risk Factors | 11 | 2025 | 5399 | 0.780 |
Why?
|
| Neoplasms | 3 | 2023 | 1357 | 0.770 |
Why?
|
| Water Intoxication | 1 | 2022 | 1 | 0.760 |
Why?
|
| Polydipsia, Psychogenic | 1 | 2022 | 1 | 0.760 |
Why?
|
| Resuscitation | 1 | 2023 | 68 | 0.750 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 149 | 0.730 |
Why?
|
| Disease Progression | 8 | 2026 | 1210 | 0.690 |
Why?
|
| Liver Cirrhosis | 1 | 2023 | 181 | 0.680 |
Why?
|
| Kidney Transplantation | 1 | 2024 | 326 | 0.680 |
Why?
|
| Coronavirus | 1 | 2020 | 14 | 0.660 |
Why?
|
| ADAM17 Protein | 1 | 2020 | 8 | 0.660 |
Why?
|
| Renal Dialysis | 4 | 2019 | 191 | 0.640 |
Why?
|
| Lactic Acid | 1 | 2020 | 75 | 0.630 |
Why?
|
| Adult | 18 | 2025 | 17239 | 0.630 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 63 | 0.620 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 140 | 0.610 |
Why?
|
| Incidence | 6 | 2025 | 1410 | 0.600 |
Why?
|
| Renal Insufficiency | 2 | 2024 | 67 | 0.580 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 178 | 0.570 |
Why?
|
| Diabetes Mellitus | 3 | 2025 | 554 | 0.570 |
Why?
|
| Heart Failure | 3 | 2023 | 944 | 0.570 |
Why?
|
| Hypertension | 5 | 2025 | 609 | 0.550 |
Why?
|
| Hyperoxaluria | 3 | 2024 | 10 | 0.520 |
Why?
|
| Aged | 18 | 2025 | 14843 | 0.490 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2020 | 45 | 0.480 |
Why?
|
| Middle Aged | 16 | 2025 | 18115 | 0.470 |
Why?
|
| Risk Assessment | 5 | 2025 | 2091 | 0.470 |
Why?
|
| Female | 23 | 2025 | 33762 | 0.460 |
Why?
|
| Prospective Studies | 7 | 2024 | 3299 | 0.450 |
Why?
|
| Vascular Access Devices | 1 | 2015 | 15 | 0.440 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2015 | 43 | 0.440 |
Why?
|
| Male | 21 | 2025 | 30809 | 0.430 |
Why?
|
| Patient Preference | 1 | 2015 | 86 | 0.420 |
Why?
|
| Prognosis | 5 | 2025 | 1773 | 0.410 |
Why?
|
| Renin-Angiotensin System | 2 | 2026 | 22 | 0.400 |
Why?
|
| Bleaching Agents | 1 | 2013 | 6 | 0.390 |
Why?
|
| Sodium Hypochlorite | 1 | 2013 | 12 | 0.390 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 383 | 0.390 |
Why?
|
| Diuretics | 2 | 2025 | 58 | 0.380 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 34 | 0.370 |
Why?
|
| Patient Safety | 1 | 2015 | 246 | 0.360 |
Why?
|
| Receptors, Mineralocorticoid | 2 | 2022 | 4 | 0.360 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 256 | 0.360 |
Why?
|
| Republic of Korea | 2 | 2024 | 201 | 0.360 |
Why?
|
| Cause of Death | 2 | 2024 | 222 | 0.360 |
Why?
|
| Puerperal Disorders | 1 | 2011 | 15 | 0.350 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2011 | 12 | 0.350 |
Why?
|
| Cohort Studies | 5 | 2025 | 2603 | 0.330 |
Why?
|
| Mother-Child Relations | 1 | 2011 | 46 | 0.330 |
Why?
|
| Machine Learning | 2 | 2024 | 192 | 0.330 |
Why?
|
| Signal Transduction | 1 | 2020 | 3148 | 0.320 |
Why?
|
| United States | 4 | 2024 | 8050 | 0.280 |
Why?
|
| Pneumonia | 1 | 2011 | 291 | 0.270 |
Why?
|
| Albumins | 2 | 2024 | 43 | 0.260 |
Why?
|
| Recovery of Function | 3 | 2024 | 289 | 0.250 |
Why?
|
| Time Factors | 3 | 2025 | 3753 | 0.240 |
Why?
|
| Communication | 1 | 2011 | 593 | 0.240 |
Why?
|
| Aldosterone | 2 | 2022 | 18 | 0.230 |
Why?
|
| Potassium | 2 | 2022 | 97 | 0.230 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2024 | 16 | 0.220 |
Why?
|
| Pancreas | 1 | 2025 | 154 | 0.220 |
Why?
|
| Nephrologists | 1 | 2024 | 7 | 0.220 |
Why?
|
| Waist Circumference | 1 | 2024 | 47 | 0.220 |
Why?
|
| Osteopontin | 1 | 2024 | 21 | 0.220 |
Why?
|
| Stroke | 2 | 2024 | 1205 | 0.210 |
Why?
|
| Foreign-Body Migration | 1 | 2024 | 24 | 0.210 |
Why?
|
| Angiotensins | 2 | 2020 | 3 | 0.200 |
Why?
|
| Device Removal | 1 | 2024 | 64 | 0.200 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2024 | 74 | 0.200 |
Why?
|
| Kidney Glomerulus | 1 | 2023 | 23 | 0.200 |
Why?
|
| Aphasia | 1 | 2024 | 47 | 0.200 |
Why?
|
| Cystatin C | 1 | 2023 | 9 | 0.200 |
Why?
|
| Atrial Appendage | 1 | 2024 | 41 | 0.200 |
Why?
|
| Fluid Therapy | 1 | 2023 | 45 | 0.190 |
Why?
|
| Apolipoprotein L1 | 1 | 2022 | 6 | 0.190 |
Why?
|
| Neovascularization, Pathologic | 1 | 2023 | 140 | 0.190 |
Why?
|
| Proteomics | 1 | 2024 | 291 | 0.180 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2022 | 6 | 0.180 |
Why?
|
| Canagliflozin | 1 | 2022 | 6 | 0.180 |
Why?
|
| India | 2 | 2024 | 164 | 0.180 |
Why?
|
| Body Mass Index | 2 | 2024 | 885 | 0.180 |
Why?
|
| Models, Immunological | 1 | 2022 | 86 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 2483 | 0.180 |
Why?
|
| Chronic Disease | 1 | 2024 | 745 | 0.170 |
Why?
|
| Patient Selection | 1 | 2024 | 483 | 0.170 |
Why?
|
| Young Adult | 2 | 2024 | 4773 | 0.170 |
Why?
|
| Hypophosphatemia, Familial | 1 | 2020 | 4 | 0.170 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins, Type IIa | 1 | 2020 | 4 | 0.170 |
Why?
|
| Nephrolithiasis | 1 | 2020 | 8 | 0.160 |
Why?
|
| Ascites | 1 | 2020 | 22 | 0.160 |
Why?
|
| Glucosides | 1 | 2020 | 15 | 0.160 |
Why?
|
| Ions | 1 | 2020 | 54 | 0.160 |
Why?
|
| Osmolar Concentration | 1 | 2020 | 90 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 727 | 0.160 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 67 | 0.160 |
Why?
|
| Vasodilation | 1 | 2020 | 36 | 0.160 |
Why?
|
| Atherosclerosis | 1 | 2022 | 159 | 0.160 |
Why?
|
| Lung Injury | 1 | 2020 | 36 | 0.160 |
Why?
|
| Drainage | 1 | 2020 | 153 | 0.150 |
Why?
|
| Benzhydryl Compounds | 1 | 2020 | 61 | 0.150 |
Why?
|
| Drug Discovery | 1 | 2020 | 95 | 0.150 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2019 | 34 | 0.150 |
Why?
|
| Immunity | 1 | 2020 | 108 | 0.150 |
Why?
|
| Virus Internalization | 1 | 2020 | 91 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 167 | 0.150 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 2679 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 734 | 0.140 |
Why?
|
| Calcium | 1 | 2022 | 583 | 0.140 |
Why?
|
| Maternal Mortality | 1 | 2018 | 16 | 0.140 |
Why?
|
| Infant Mortality | 1 | 2018 | 21 | 0.140 |
Why?
|
| Pregnancy | 2 | 2018 | 2363 | 0.130 |
Why?
|
| Treatment Outcome | 3 | 2024 | 5764 | 0.130 |
Why?
|
| Oxalates | 3 | 2024 | 19 | 0.130 |
Why?
|
| Gene Expression | 1 | 2020 | 856 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 798 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 5565 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2018 | 373 | 0.120 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 197 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 918 | 0.120 |
Why?
|
| Comorbidity | 2 | 2025 | 1115 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2024 | 869 | 0.110 |
Why?
|
| United Kingdom | 2 | 2025 | 85 | 0.110 |
Why?
|
| Algorithms | 1 | 2020 | 1033 | 0.110 |
Why?
|
| Vascular Grafting | 1 | 2015 | 37 | 0.110 |
Why?
|
| Coronary Disease | 2 | 2012 | 246 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2015 | 127 | 0.100 |
Why?
|
| Prevalence | 1 | 2018 | 1434 | 0.100 |
Why?
|
| Infant, Newborn | 1 | 2018 | 1409 | 0.100 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 159 | 0.100 |
Why?
|
| Infant | 1 | 2018 | 1682 | 0.100 |
Why?
|
| Patient Participation | 1 | 2015 | 231 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 1556 | 0.090 |
Why?
|
| Vascular Surgical Procedures | 1 | 2015 | 240 | 0.090 |
Why?
|
| Suicide, Attempted | 1 | 2013 | 111 | 0.090 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2011 | 8 | 0.090 |
Why?
|
| Neurologic Examination | 1 | 2011 | 53 | 0.090 |
Why?
|
| Obesity | 1 | 2019 | 1263 | 0.080 |
Why?
|
| Child | 1 | 2020 | 4598 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 214 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 1656 | 0.080 |
Why?
|
| Patients | 1 | 2011 | 114 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2012 | 316 | 0.080 |
Why?
|
| Health Behavior | 1 | 2011 | 482 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 705 | 0.060 |
Why?
|
| Health Promotion | 1 | 2011 | 512 | 0.060 |
Why?
|
| Mice | 1 | 2020 | 11100 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 768 | 0.060 |
Why?
|
| Organ Size | 1 | 2025 | 173 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2020 | 6811 | 0.060 |
Why?
|
| Biological Specimen Banks | 1 | 2025 | 23 | 0.060 |
Why?
|
| Tenascin | 1 | 2024 | 4 | 0.050 |
Why?
|
| Kidney Tubules | 1 | 2024 | 23 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2024 | 84 | 0.050 |
Why?
|
| Curcuma | 1 | 2024 | 2 | 0.050 |
Why?
|
| Aortography | 1 | 2024 | 58 | 0.050 |
Why?
|
| Aorta, Abdominal | 1 | 2024 | 56 | 0.050 |
Why?
|
| Embolism | 1 | 2024 | 41 | 0.050 |
Why?
|
| Urinalysis | 1 | 2023 | 37 | 0.050 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 116 | 0.050 |
Why?
|
| Prosthesis Design | 1 | 2024 | 218 | 0.050 |
Why?
|
| Proteinuria | 1 | 2023 | 42 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2024 | 140 | 0.050 |
Why?
|
| Urea | 1 | 2022 | 41 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 60 | 0.050 |
Why?
|
| Renal Elimination | 1 | 2022 | 3 | 0.050 |
Why?
|
| Adolescent | 1 | 2013 | 6290 | 0.050 |
Why?
|
| Cardiac Catheterization | 1 | 2024 | 292 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 21309 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 454 | 0.040 |
Why?
|
| Thrombosis | 1 | 2024 | 205 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2024 | 234 | 0.040 |
Why?
|
| Phosphorus | 1 | 2020 | 16 | 0.040 |
Why?
|
| Renin | 1 | 2020 | 10 | 0.040 |
Why?
|
| Genotype | 1 | 2022 | 670 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 575 | 0.040 |
Why?
|
| Plasma | 1 | 2020 | 38 | 0.040 |
Why?
|
| Transcriptome | 1 | 2023 | 396 | 0.040 |
Why?
|
| Boston | 1 | 2020 | 257 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2021 | 274 | 0.040 |
Why?
|
| Sex Factors | 1 | 2022 | 989 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 460 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2021 | 479 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2019 | 150 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 1231 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 989 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 953 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2025 | 2238 | 0.030 |
Why?
|
| Brain | 1 | 2024 | 1594 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2021 | 828 | 0.030 |
Why?
|
| Inflammation | 1 | 2019 | 1187 | 0.020 |
Why?
|
| Cholesterol | 1 | 2011 | 261 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 525 | 0.020 |
Why?
|
| Smoking | 1 | 2011 | 860 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 959 | 0.010 |
Why?
|